The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 05, 2016

Filed:

Jul. 27, 2012
Applicants:

Ji Han Kim, Seoul, KR;

Je Hak Kim, Gyeonggi-do, KR;

Joon Kwang Lee, Gyeonggi-do, KR;

Hahn-sun Jung, Gyeonggi-do, KR;

Nam Seok Han, Gyeonggi-do, KR;

Yong Park, Gyeonggi-do, KR;

Seung-hoon Kang, Gyeonggi-do, KR;

Hee Jin Jeong, Gyeonggi-do, KR;

Kyung-tae Lee, Seoul, KR;

Hye Eun Choi, Seoul, KR;

Yong Ha Chi, Gyeonggi-do, KR;

Joo Han Lee, Seoul, KR;

Soo Heui Paik, Gyeonggi-do, KR;

Inventors:

Ji Han Kim, Seoul, KR;

Je Hak Kim, Gyeonggi-do, KR;

Joon Kwang Lee, Gyeonggi-do, KR;

Hahn-Sun Jung, Gyeonggi-do, KR;

Nam Seok Han, Gyeonggi-do, KR;

Yong Park, Gyeonggi-do, KR;

Seung-Hoon Kang, Gyeonggi-do, KR;

Hee Jin Jeong, Gyeonggi-do, KR;

Kyung-Tae Lee, Seoul, KR;

Hye Eun Choi, Seoul, KR;

Yong Ha Chi, Gyeonggi-do, KR;

Joo Han Lee, Seoul, KR;

Soo Heui Paik, Gyeonggi-do, KR;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 213/02 (2006.01); C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 213/82 (2006.01); C07D 495/04 (2006.01); C07D 413/14 (2006.01); C07D 417/14 (2006.01);
U.S. Cl.
CPC ...
C07D 401/14 (2013.01); C07D 213/82 (2013.01); C07D 401/12 (2013.01); C07D 413/14 (2013.01); C07D 417/14 (2013.01); C07D 495/04 (2013.01);
Abstract

Disclosed are an anti-angiogenic compound, represented by Chemical Formula I, or a pharmaceutically acceptable salt thereof, a preparation method thereof, and a pharmaceutically acceptable composition including the same. Because the compound of Chemical Formula I potently suppresses the angiogenesis, the compound of Chemical Formula I is applicable to the prevention and treatment of diseases caused by aberrant activity of vascular endothelial growth factor, and available as an anti-angiogenic agent.


Find Patent Forward Citations

Loading…